ReviewDrug design, development and therapy2025
The Role of Mitochondrial Dysfunction in Sepsis-Associated Acute Kidney Injury: A Narrative Review.
Review in Drug design, development and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- Targeting integrated cell death networks in sepsis‑associated acute kidney injury: Shared regulatory nodes and diet‑related small molecule modulation (Review).International journal of molecular medicine · 2026Review
- Mapping the knowledge landscape and identifying frontiers of mitochondrial dysfunction in sepsis-associated acute kidney injury: a four-decade bibliometric and visualized analysis.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Mitochondrial lipid remodeling in sepsis-associated acute kidney injury: a cardiolipin-centered convergence framework.Archives of toxicology · 2026Review
- Research Progress on the Treatment of Renal Injury with Esculetin: Multi-Target Pharmacological Mechanism and Clinical Translation Prospect.International journal of molecular sciences · 2026Review
- Research progress on biomarkers for acute kidney injury in children.Pediatric nephrology (Berlin, Germany) · 2026Review
- A Comprehensive Review on the Cardioprotective and Nephroprotective Effects of Semaglutide, and Its Therapeutic Efficacy and Mechanisms in Cardiorenal Syndrome.Drug design, development and therapy · 2026Review
- Development and internal validation of a prediction model for early identification of sepsis-associated acute kidney injury based on admission serum biomarkers: a retrospective cohort study.Frontiers in medicine · 2026Article
- Utility of Restricted Mean Survival Time Analysis for Renal Replacement Therapy in Patients with Sepsis Associated Acute Kidney Injury: A Retrospective Study.International journal of general medicine · 2026Article
- Mitochondrial immunometabolism in sepsis: bridging immune cell dysfunction and organ failure.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sepsis-associated acute kidney injury (SA-AKI) is one of the most frequent complications of sepsis and one of the leading causes of acute kidney injury (AKI), posing a significant threat to patient survival. The pathogenesis of SA-AKI has been linked to mitochondrial dysfunction, according to emerging evidence. Mitochondria serve as the primary energy-producing organelles in cells, and mitochondrial dysfunction can result in insufficient renal energy supply, oxidative stress, and inflammatory responses, all of which can both initiate and exacerbate SA-AKI. Thus, elucidating the role of mitochondrial dysfunction in SA-AKI is of critical importance. Starting from the fundamental mechanisms of mitochondrial dysfunction, this review draws upon more than 130 relevant publications through August 2025, comprehensively summarizes the role of mitochondrial dysfunction in the pathophysiological processes of SA-AKI and the drugs for treating SA-AKI through the improvement of mitochondrial function, while also discussing in detail the potential therapeutic applications of several well-characterized therapeutic targets in SA-AKI, providing important insights into the diagnosis and treatment of this disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.